Biosimilars: Three things you need to know
We've had the good fortune to work with a biosimilars client this year. Working in this space has given us an opportunity to read and listen to many experts in…
Menu
Geographic Diversity at BIO Europe 2012
As we've done in the past, we've tabulated the countries of origin from the stack of business card collected at BIO Europe 2012. Our "rules" for this analysis are simple.…
BIOEurope 2012: Does size matter?
We’ve returned from BIO Europe 2012 in Hamburg with a stack of business cards, pages of meeting notes, prioritized follow ups, and some great memories. We managed to completely fill…
What is innovation?
Bruce Booth (yet again) published a terrific post on his blog, entitled "NextWave of Pharma Innovation?" His premise is that reformulations, like the once-daily liquid methylphenidate product, Quillivant XR, is not…
Repositioned Drugs Surpass New Brands
There are some very interesting data published yesterday on FDA approval statistics: It was in 1984 when FDA first added the 505(b)(2) pathway for drug approval, a hybrid between the…
Observations from AAPS in Chicago
We spent a few days in Chicago attending the AAPS Convention. As usual, it was jammed with excellent science, tons of exhibitors, and great opportunities to catch up with old…
Lacerta Bio at AAPS Chicago
Next week, Lacerta Bio will be at the AAPS Annual Meeting in Chicago. If you have plans to attend, drop us a note! To follow the action on Twitter, use…
Compounding Pharmacists & NECC
When we studied pharmacy, compounding was in integral part of our education. On a weekly basis, we compounded just about everything: creams, lotions, elixirs, suspensions, parenterals, capsules (by hand), etc.,…
But who will pay?
An intriguing graph was posted on Twitter the other day: Now we understand the argument, and it's a good one: As the population ages, there will be more long-term illness,…
More Me-Too Products, Not Fewer
An article by our good friend Derek Hennecke in the September issue of Drug Development & Delivery really struck a nerve with us...but in a good way. To quote (with…
- Go to the previous page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- 25
- 26
- …
- 33
- Go to the next page